Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Ulodesine succinate anhydrous

Copy Product Info
😃Good
Catalog No. T202983Cas No. 1246200-39-4
Alias Ulodesine, DADMe-immucillin H, BCX-4208, BCX4208, BCX 4208

Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.

Ulodesine succinate anhydrous
Other Forms of Ulodesine succinate anhydrous:
UlodesineT67822L548486-59-5
In Stock
View details

Ulodesine succinate anhydrous

Copy Product Info
😃Good
Catalog No. T202983Alias Ulodesine, DADMe-immucillin H, BCX-4208, BCX4208, BCX 4208Cas No. 1246200-39-4
Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mgInquiry10-14 weeks10-14 weeks
50 mgInquiry10-14 weeks10-14 weeks
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.
SynonymsUlodesine, DADMe-immucillin H, BCX-4208, BCX4208, BCX 4208
Chemical Properties
Molecular Weight323.325
FormulaC12H16N4O3 1/2C4H6O4
Cas No.1246200-39-4
SmilesOC(CCC(O)=O)=O.O=C(N=CN1)C2=C1C(CN3C[C@@H]([C@H](C3)O)CO)=CN2.O=C(N=CN4)C5=C4C(CN6C[C@@H]([C@H](C6)O)CO)=CN5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Ulodesine succinate anhydrous | purchase Ulodesine succinate anhydrous | Ulodesine succinate anhydrous cost | order Ulodesine succinate anhydrous | Ulodesine succinate anhydrous chemical structure | Ulodesine succinate anhydrous formula | Ulodesine succinate anhydrous molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.